RMOC Style Generic Shared Care Request Form(73 KB) - Shared care agreement
For use from a date to be agreed in December.
Date added: 14th Nov 2022
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| AMILORIDE | Orange | Heart failure and hypertension in infants and children | |
| ATOMOXETINE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents
|
| AZATHIOPRINE | Orange | Dermatological disease | |
| BECLOMETASONE/FORMETEROL/GLYCOPYRRONIUM (Trimbow ®) (NEW) | Do not prescribe | Asthma |
As per the Respiratory Prescribing Group September 22 Different strengths are licensed for different indications – please check the BNF |
| CAPTOPRIL | Orange | Heart failure and hypertension in infants and children | |
| DEXAMFETAMINE | Orange | Attention deficit hyperactivity disorder (ADHD) |
Adults Children and adolescents |
| ENALAPRIL | Orange | Heart failure and hypertension in infants and children | |
| FUROSEMIDE | Orange | Heart failure and hypertension in infants and children | |
| GLYCOPYRONIUM/BECLOMETASONE/FORMETEROL DPI (Trimbow NEXThaler) | Green | Maintenance treatment of adults with moderate to severe COPD |
Reviewed by the Respiratory Prescribing Group September 2021
|
| GLYCOPYRRONIUM / BECLOMETASONE / FORMOTEROL metered dose Inhaler (Trimbow®) | Green | Maintenance of COPD. |
Different strengths are licensed for different indications – please check the BNF |
| GUANFACINE | Orange | ADHD - Adult |
Adult Full SCA and Request Form |
| GUANFACINE | Orange | ADHD - Peadiatric |
Paediatric Full SCA and Request Form |
| LISDEXAMFETAMINE DIMESYLATE | Orange | ADHD when response to methylphenidate is inadequate |
Adults Children and adolescents |
| LISINOPRIL | Orange | Heart failure and hypertension in infants and children | |
| LITHIUM SALTS | Orange | Mania, Bipolar Disorder, Recurrent Depression or Aggressive or Self-mutilating behaviour. | |
| LOSARTAN | Orange | Heart failure and hypertension in infants and children | |
| METHOTREXATE Oral | Orange | Dermatological disease | |
| METHYLPHENIDATE (+'CR') | Orange | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care. |
| SPIRONOLACTONE | Orange | Heart failure and hypertension in infants and children | |
| TESTOSTERONE | Orange | Replacement therapy in children and adolescents | |
| VENLAFAXINE | Orange | Treatment resistant depression - high dose (≥300mg) |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLRAPC Newsletter – November 22(675 KB) - LMSG/LLR APC newsletters
Date added: 11th Nov 2022
Acarizax Shared Care Agreement Request form(75 KB) - Shared care agreement
From 1st December 2022
Date added: 10th Nov 2022
Acarizax Shared Care Agreement(209 KB) - Shared care agreement
From 1st December 2022
Date added: 9th Nov 2022
Toolkit to support sustainable inhaler prescribing(536 KB) - Guidelines
Version 1 Uploaded November 2022
Date added: 8th Nov 2022
Useful opioid prescribing links(316 KB) - Guidelines
Uploaded November 2022
Date added: 10th Aug 2021
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more